ClinicalTrials.gg
TerminatedNCT02055781PAC326Updated Nov 18, 2021Results posted

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

A Phase 3 interventional study of Pacritinib and Best Available Therapy in Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis, sponsored by CTI BioPharma. Terminated at 122 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
311
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.

Enrollment
3rd of 18
311 · median 35
Started
2014
with 1 other
Phase 3
3 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
5 of 18
CTI BioPharma

Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 3, and was the 4th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pacritinib

pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing pacritinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.

Read the detailed description

Multicenter, randomized, controlled, phase 3 trial comparing the safety and efficacy of pacritinib with that of BAT in patients with thrombocytopenia and primary or secondary myelofibrosis. Approximately 300 eligible patients will be randomized in a 1:1:1 allocation to pacritinib 400 mg dosed QD, pacritinib 200 mg dosed BID, or BAT (includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry). Spleen volume will be measured by MRI or CT at baseline and every 12 weeks thereafter. An independent radiology facility (IRF), blind to treatment assignments, will measure spleen volumes. Patients will also be followed for safety, Leukemia Free Survival (LFS), Overall Survival (OS), frequency of red blood cell (RBC) and platelet transfusions, and other exploratory endpoints. An Independent Data Monitoring Committee (IDMC) will evaluate the safety of pacritinib.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Keywords

  • Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis
  • Primary Myelofibrosis
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Bone Marrow Disease
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Splenomegaly
  • Pacritinib
  • MPN-SAF
  • MPN-SAF TSS
  • Anemia
  • Myeloproliferative Neoplasm
  • Spleen volume
  • Thrombocytopenia
  • SB1518
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Intermediate -1 or -2 or high-risk Myelofibrosis (per Passamonti et al 2010)
  • Thrombocytopenia ( count ≤ 100,000/µL) at any time after signing
  • Palpable splenomegaly ≥ 5 cm on physical examination
  • Total Symptom Score ≥ 13 on the MPN-SAF TSS 2.0, not including the inactivity question
  • Patients who are platelet or red blood cell transfusion-dependent are eligible
  • Adequate white blood cell counts (with low blast counts), liver function, and renal function
  • At least 6 months from prior splenic irradiation
  • At least 1-4 weeks since prior myelofibrosis therapy, including any erythropoietic or thrombopoietic agent
  • Not pregnant, not lactating, and agree to use effective
  • Able and willing to undergo frequent MRI or CT assessments and complete symptom assessments using a patient-reported outcome instrument

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with more than 2 JAK2 inhibitors or with pacritinib
  • There is no maximum cumulative prior JAK2 inhibitor treatment
  • History of (or plans to undergo) spleen removal surgery or stem cell transplant
  • Ongoing gastrointestinal medical condition such as Crohn's disease, Inflammatory bowel disease, chronic diarrhea, or constipation
  • Active bleeding that requires hospitalization during the screening period
  • Cardiovascular disease, including recent history or currently clinically symptomatic and uncontrolled: congestive heart failure, arrhythmia, angina, prolongation or other QTc risk factors, myocardial infarction
  • Other within last 3 years other than certain limited skin, cervical, prostate, breast, or bladder cancers
  • Other ongoing, uncontrolled illnesses (including infection and active hepatitis A, B, or C), psychiatric disorder, or social situation that would prevent good care on this study
  • \< 6 months
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
311 participants (actual)

Study arms

  • Experimental
    Pacritinib, Once Daily

    Pacritinib 400 mg QD

    Drug: Pacritinib

  • Experimental
    Pacritinib, Twice Daily

    Pacritinib 200 mg BID

    Drug: Pacritinib

  • Active comparator
    Best Available Therapy

    BAT includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry.

    Drug: Best Available Therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Spleen Volume Reduction

    Proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT).

    Time frame: Baseline to Week 24

  2. Total Symptom Score (TSS) Reduction

    Proportion of patients achieving a ≥ 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.

    Time frame: Baseline to Week 24

07

Results

Posted Nov 18, 2021

Participant flow

Participant flow — Overall Study
MilestonePacritinib, QDPacritinib, BIDBest Available Therapy
Started104107100
Completed627963
Not completed422837

Outcome measures

PrimarySpleen Volume Reduction

Proportion of patients achieving a ≥ 35% reduction in spleen volume from baseline to week 24 as measured by magnetic resonance imaging (MRI) or computed tomography (CT).

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Spleen Volume Reduction
ParticipantsPacritinib, Once DailyPacritinib, Twice DailyBest Available Therapy
Spleen Volume Reduction11162
Statistical analysis
  • Pacritinib, Once Daily vs Pacritinib, Twice Daily vs Best Available Therapy · Fisher Exact · p = 0.0011
  • Pacritinib, Once Daily vs Best Available Therapy · Fisher Exact · p = 0.0173
  • Pacritinib, Twice Daily vs Best Available Therapy · Fisher Exact · p = 0.0007
PrimaryTotal Symptom Score (TSS) Reduction

Proportion of patients achieving a ≥ 50% reduction in the total symptom score from baseline to Week 24 on the Myeloproliferative Neoplasm Symptom Assessment Form 2.0 (MPN-SAF TSS 2.0). Responses (on a scale from 0 \[absent\] to 10 \[worst imaginable\]) to questions about symptoms (tiredness, early satiety, abdominal discomfort, night sweats, pruritus, bone pain, and pain under the ribs on the left side) were used to calculate the TSS.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Total Symptom Score (TSS) Reduction
ParticipantsPacritinib, Once DailyPacritinib, Twice DailyBest Available Therapy
Total Symptom Score (TSS) Reduction132410
Statistical analysis
  • Pacritinib, Once Daily vs Pacritinib, Twice Daily vs Best Available Therapy · Fisher Exact · p = 0.0791
  • Pacritinib, Once Daily vs Best Available Therapy · Fisher Exact · p = 0.6524
  • Pacritinib, Twice Daily vs Best Available Therapy · Fisher Exact · p = 0.0106

Adverse events

Collected over From the time of signing informed consent through 30 days after the last study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pacritinib, Once Daily22/104 (21.2%)48/104 (46.2%)104/104 (100%)
Pacritinib, Twice Daily20/107 (18.7%)50/106 (47.2%)100/106 (94.3%)
Best Available Therapy20/100 (20%)30/98 (30.6%)87/98 (88.8%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventPacritinib, Once DailyPacritinib, Twice DailyBest Available Therapy
AnaemiaBlood and lymphatic system disorders5/1048/1063/98
ThrombocytopeniaBlood and lymphatic system disorders2/1046/1062/98
PneumoniaInfections and infestations5/1046/1064/98
Renal failure acuteRenal and urinary disorders5/1042/1062/98
Disease progressionGeneral disorders4/1043/1063/98
Cardiac failureCardiac disorders1/1044/1062/98
Atrial fibrillationCardiac disorders3/1040/1063/98
Urinary tract infectionInfections and infestations3/1040/1060/98
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1043/1060/98
PyrexiaGeneral disorders2/1043/1062/98
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPacritinib, Once DailyPacritinib, Twice DailyBest Available Therapy
DiarrhoeaGastrointestinal disorders70/10451/10615/98
NauseaGastrointestinal disorders39/10434/10611/98
ThrombocytopeniaBlood and lymphatic system disorders34/10436/10623/98
AnaemiaBlood and lymphatic system disorders29/10425/10615/98
VomitingGastrointestinal disorders22/10420/1065/98
Oedema peripheralGeneral disorders14/10421/10615/98
Abdominal painGastrointestinal disorders20/10410/10619/98
FatigueGeneral disorders18/10418/10616/98
DizzinessNervous system disorders15/10416/1065/98
PyrexiaGeneral disorders11/10416/1063/98

Baseline characteristics

Represents Intent To Treat population (number of randomized patients)

Age, Categorical
Age, Categorical(Participants)Pacritinib, Once DailyPacritinib, Twice DailyBest Available TherapyTotal
<=18 years324132105
Between 18 and 65 years706568203
>=65 years2103
Age, Continuous
Age, Continuous(years)Pacritinib, Once DailyPacritinib, Twice DailyBest Available TherapyTotal
Mean69 ± 8.5565.9 ± 8.7566.9 ± 9.7567.2 ± 9.01
Sex: Female, Male
Sex: Female, Male(Participants)Pacritinib, Once DailyPacritinib, Twice DailyBest Available TherapyTotal
Female514445140
Male536355171
Region of Enrollment
Region of Enrollment(Participants)Pacritinib, Once DailyPacritinib, Twice DailyBest Available TherapyTotal
New Zealand46313
Canada52411
Netherlands0112
Belgium2215
Hungary98724
United States444443131
Czechia24511
United Kingdom5111127
Australia45413
France810927
Germany104317
Russia1110930
08

Study locations

122 sites
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85715, United States
  • City of Hope
    Duarte, California 91010, United States
  • Moores Cancer Centre
    La Jolla, California 92093, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Rocky Mountain Cancer Center
    Boulder, Colorado 80303, United States
  • George Washington University- Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • SCRI- Florida Cancer Specialists South Region
    Fort Myers, Florida 33916, United States
  • SCRI - Florida Cancer Specialists North Region
    Saint Petersburg, Florida 33705, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Indiana University Goshen Cancer Centre
    Goshen, Indiana 46526, United States
  • Investigative Clinical Research of Indiana
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Siouxland Hematology-Oncology Associates, L.L.P (SHOA)
    Sioux City, Iowa 51101, United States
  • Norton Cancer Institute, Suburban
    Louisville, Kentucky 40207, United States
  • St Joseph Mercy Hospital
    Ann Arbor, Michigan 48106, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Providence Cancer Institute
    Southfield, Michigan 48075, United States
  • Washington University School of Medicine Division of Oncology
    Saint Louis, Missouri 63110, United States
  • Nebraska Hematology-Oncology, P.C.
    Lincoln, Nebraska 68506, United States
  • Hackensack University
    Hackensack, New Jersey 07601, United States
  • Hematology-Oncology Associates of Northern Jersey
    Morristown, New Jersey 07962, United States
  • New Mexico Cancer Care Alliance
    Albuquerque, New Mexico 87106, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • SCRI-Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic-Taussig Cancer Center
    Cleveland, Ohio 44195, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Upstate Oncology Associates
    Greenville, South Carolina 29601, United States
  • Sarah Cannon Research Institute (SCRI)
    Nashville, Tennessee 37203, United States
  • Texas Onocolgy-Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • UTMB Galveston
    Galveston, Texas 77555, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78229, United States
  • Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Specialists
    Leesburg, Virginia 20176, United States
  • Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Green Bay Oncology
    Green Bay, Wisconsin 54301, United States
  • Froedtert Hospital and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Health - Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Perth Blood Institute
    Nedlands, Western Australia 6009, Australia
  • Haematology and Oncology Clinics of Australia
    Chermside, 4032, Australia
  • Prince of Wales Hospital
    Randwick, 2031, Australia
  • Centre Hospitalier de Jolimont-Lobbes
    Haine-Saint-Paul, Hainaut, Belgium
  • ZNA - Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint Jan Brugge-Oostende AV
    Brugge, 8000, Belgium
  • Hopital Brugmann
    Brussels, 1020, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • St Augustinus
    Wilrijk, 2610, Belgium
  • UC Louvain
    Yvoir, 5530, Belgium
  • Saint John Regional Hospital
    Saint John, New Brunswick E2L 4L2, Canada
  • Princess Margaret Cancer Center
    Toronto, Ontario M5G2M9, Canada
  • Fakultní nemocnice Brno
    Brno, NAP 62500, Czechia
  • Faculty Hospital Olomouc
    Olomouc, NAP 775 20, Czechia
  • Fakultní nemocnice Plzeň
    Plzeň, NAP 30460, Czechia
  • University Hospital Hradec Kralove
    Králová, 500 05, Czechia
  • Chu d'Amiens Hopital Sud
    Amiens, Cedex 1 80054, France
  • Hôpital Caremeau
    Nimes, Cedex 9 30029, France
  • CHU Rennes
    Rennes, Cedex 9 35033, France
  • CHU Purpan
    Toulouse, Cedex 9 31059, France
  • CH de Mulhouse
    Mulhouse, Cedex 68070, France
  • CHU de CAEN
    Caen, 14000, France
  • Centre Hospitalier de Lens
    Lens, 62300, France
  • Hopital l'Archet, CHU de Nice
    Nice, BP 30 79 06202, France
  • Saint Antoine Hospital
    Paris, 75012, France
  • Centre Hospitalier Lyon Sud
    Pierre Benite, 69495, France
  • CHU de Strasbourg
    Strasbourg, 67091, France
  • Institut Gustave Roussy
    Villejuif Cedex, 94805, France
  • Charite-Medical University
    Berlin, 12203, Germany
  • Gemeinschaftspraxis Hämatologie/Onkologie
    Dresden, 01307, Germany
  • University Hospital Essen
    Essen, D-45122, Germany
  • Uniklinik Freiburg
    Freiburg, 79106, Germany
  • Universitatsklinikum Halle (Saale)
    Halle (Saale), 06120, Germany
  • Klinik I fur Innere Medizin, Universitat Koln
    Koln, 50924, Germany
  • University Hospital Leipzig
    Leipzig, 04103, Germany
  • Städtisches Klinikum München GmbH
    Munchen, 81737, Germany
  • University of Munster
    Munster, 48149, Germany
  • University Hospital Ulm
    Ulm, 89081, Germany
  • Semmelweis Egyetem AOK
    Budapest, 1083, Hungary
  • University of Debrecen, Belgyogyaszati Intezet
    Debrecen, 4032, Hungary
  • Bekes Megyei Pandy Kalman Korhaz
    Gyula, 5700, Hungary
  • Kaposi Mór Oktató Kórház
    Kaposvár, 7400, Hungary
  • SZTE II. sz Belgyogyoszati Klinika es Kardiologiai Kozpont
    Szeged, 6720, Hungary
  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőint
    Szolnok, 5004, Hungary
  • University Hospital Maastricht
    Maastricht, 6229 HX, Netherlands
  • Erasmus MC
    Rotterdam, 3015 CE, Netherlands

Showing the first 100 of 122 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, Szoke A, Drummond M, Pristupa A, Granston T, Daly R, Al-Fayoumi S, Callahan JA, Singer JW, Gotlib J, Jamieson C, Harrison C, Mesa R, Verstovsek S. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818. PubMed 29522138 ↗
  • Verstovsek S, Mesa R, Talpaz M, Kiladjian JJ, Harrison CN, Oh ST, Vannucchi AM, Rampal R, Scott BL, Buckley SA, Craig AR, Roman-Torres K, Mascarenhas JO. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica. 2022 Jul 1;107(7):1599-1607. doi: 10.3324/haematol.2021.279415. PubMed 34551507 ↗
  • Tremblay D, Mesa R, Scott B, Buckley S, Roman-Torres K, Verstovsek S, Mascarenhas J. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Adv. 2020 Dec 8;4(23):5929-5935. doi: 10.1182/bloodadvances.2020002970. PubMed 33275766 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2014 to primary completion in Apr 2016, 26 months.

Results were first posted in Nov 2021, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2014
First posted
Feb 5, 2014
StartActual
Feb 2014
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Nov 18, 2021
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02055781
Lead sponsor
CTI BioPharma
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
Feb 2014
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Nov 18, 2021
Last update
Nov 18, 2021

Study contacts

Simran Singh
study director · Sr. Director, Head of Clinical Operations

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion